Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.
Epistemonikos ID: 00fa6a0c509274ccc4d8e9913ea7773d2cafdb7f
First added on: May 12, 2024